The recently updated American Society of Clinical Oncology (ASCO) guideline recommended that patients with locally recurrent unresectable or metastatic hormone receptor positive and HER2-negative breast cancer should be subject to testing of PIK3CA mutations to determine their eligibility for treatment with the alpelisib plus fulvestrant [92]. The gene discussed is ERBB2; the disease is breast cancer.